Skip to main content
Year archive

Xbrane Biopharma — 2025 filings

All 64 regulatory filings released by Xbrane Biopharma (XBRANE) in 2025, sourced directly from the official regulator.

64 Filings
2025 Period
2025 filings (64)
Filing Released Lang
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-25 Swedish
Xbrane Biopharma resolves to issue 420,517 warrants to Fenja Capital II A/S under the conditional financing solution
Capital/Financing Update
2025-11-24 English
Xbrane Biopharma beslutar om emission av 420 517 teckningsoptioner till Fenja Capital II A/S inom ramen för villkorad finansieringslösning
Share Issue/Capital Change
2025-11-24 Swedish
XBRANE UPPDATERAR TIDPLAN FÖR ÅTERINSÄNDNING AV BLA FÖR SIN RANIBIZUMAB-BIOSIMILAR TILL FDA
Legal Proceedings Report
2025-11-19 Swedish
XBRANE UPDATES ON TIMING FOR RESUBMISSION OF THE BLA FOR ITS RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA
Legal Proceedings Report
2025-11-19 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-05 Swedish
ANTALET AKTIER OCH RÖSTER I XBRANE HAR FÖRÄNDRATS TILL FÖLJD AV TIDIGARE OFFENTLIGGJORD OMVÄND SPLIT 1:125.
Declaration of Voting Results & Voting Rights Announcements
2025-11-03 Swedish
THE NUMBER OF SHARES AND VOTES IN XBRANE HAS CHANGED AS A RESULT OF THE PREVIOUSLY ANNOUNCED REVERSE SPLIT OF 1:125.
Share Issue/Capital Change
2025-11-03 English
Interim / Quarterly Report 2025
Interim / Quarterly Report 9M 2025
2025-10-24 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report 9M 2025
2025-10-24 English
XBRANE BIOPHARMA PRESENTS THE NOMINATION COMMITTEE
Board/Management Information
2025-10-20 English
XBRANE BIOPHARMA PRESENTERAR VALBEREDNINGEN
Board/Management Information
2025-10-20 Swedish
Xbrane provides Regulatory update on FDA review of its ranibizumab biosimilar candidate
Legal Proceedings Report
2025-10-19 English
Xbrane ger regulatorisk uppdatering om FDA:s granskning av dess ranibizumab-biosimilarkandidat
Legal Proceedings Report
2025-10-19 Swedish
Xbrane Biopharma ingår villkorad finansieringslösning med Fenja Capital II A/S
Capital/Financing Update
2025-10-16 Swedish
Xbrane Biopharma enters into conditional financing solution with Fenja Capital II A/S
Capital/Financing Update
2025-10-16 English
Record date for reverse share split in Xbrane Biopharma AB
Share Issue/Capital Change
2025-10-15 English
Avstämningsdag för sammanläggning av aktier i Xbrane Biopharma AB
Share Issue/Capital Change
2025-10-15 Swedish
Announcement from extra general meeting in Xbrane Biopharma AB
AGM Information
2025-10-13 English
Kommuniké från extra bolagsstämma i Xbrane Biopharma AB
AGM Information
2025-10-13 Swedish
XBRANE BIOPHARMA AB (“XBRANE” OR THE “COMPANY”) HAS ACCORDING TO PREVIOUSLY ANNOUNCED INFORMATION RESOLVED TO CARRY OUT A DIRECTED ISSUE OF IN TOTAL 25,990,000 SHARES
Share Issue/Capital Change
2025-09-30 English
XBRANE BIOPHARMA AB ("XBRANE" ELLER "BOLAGET") HAR ENLIGT TIDIGARE OFFENTLIGGJORD INFORMATION GENOMFÖRT EN RIKTAD EMISSION OM TOTALT 25 990 000 AKTIER
Share Issue/Capital Change
2025-09-30 Swedish
NOTICE OF EXTRA GENERAL MEETING IN XBRANE BIOPHARMA AB
Proxy Solicitation & Information Statement
2025-09-10 English
KALLELSE TILL EXTRA BOLAGSSTÄMMA I XBRANE BIOPHARMA AB
Proxy Solicitation & Information Statement
2025-09-10 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report H1 2025
2025-08-26 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report H1 2025
2025-08-26 English
Xbrane Biopharma AB ("Xbrane" eller "Bolaget") har enligt tidigare offentliggjord information genomfört en riktad emission om totalt 1 017 488 260 aktier.
Share Issue/Capital Change
2025-07-31 Swedish
Xbrane Biopharma AB (“Xbrane” or the “Company”) has according to previously announced information resolved to carry out a directed issue of in total 1,017,488,260 shares.
Share Issue/Capital Change
2025-07-31 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-07-16 Swedish
Xbrane publishes disclosure document regarding admission to trading of the newly issued shares in Xbrane
Share Issue/Capital Change
2025-07-11 English
Xbrane offentliggör undantagsdokument avseende upptagande till handel av de nyemitterade aktierna i Xbrane
Share Issue/Capital Change
2025-07-11 Swedish
Kommuniké från extra bolagsstämma i Xbrane Biopharma AB
AGM Information
2025-07-03 Swedish
Announcement from extra general meeting in Xbrane Biopharma AB
AGM Information
2025-07-03 English
KALLELSE TILL EXTRA BOLAGSSTÄMMA I XBRANE BIOPHARMA AB
AGM Information
2025-06-10 Swedish
NOTICE OF EXTRA GENERAL MEETING IN XBRANE BIOPHARMA AB
AGM Information
2025-06-10 English
Xbrane har, villkorat av godkännande av en extra bolagsstämma, beslutat att genomföra en övertecknad riktad emission av aktier om cirka 240 MSEK
Share Issue/Capital Change
2025-06-10 Swedish
Xbrane has, subject to the approval by an EGM, resolved to carry out an oversubscribed directed issue of shares of approximately SEK 240 million
Share Issue/Capital Change
2025-06-10 English
Xbrane offentliggör avsikt att genomföra en riktad emission om cirka 200 MSEK
Share Issue/Capital Change
2025-06-09 Swedish
Xbrane announces its intention to carry out a directed issue of shares of approximately SEK 200 million
Share Issue/Capital Change
2025-06-09 English
Xbrane Biopharma slutför försäljning av XB003 och delar av sin organisation till Alvotech
M&A Activity
2025-06-04 Swedish
Xbrane Biopharma Completes Sale of XB003 and Parts of Its Organization to Alvotech
M&A Activity
2025-06-04 English
Xbrane Biopharma AB (publ) ("Xbrane" eller "Bolaget") (Nasdaq Stockholm: XBRANE) uppdaterar med anledning av FDA:s BLA (Biologics License Application) för sin biosimilarkandidat till LUCENTIS® (ranibi
Report Publication Announcement
2025-05-23 Swedish
Xbrane Biopharma AB (publ) ("Xbrane" or "the Company") (Nasdaq Stockholm: XBRANE) updates on US FDA BLA (Biologics License Application) for its investigational biosimilar candidate to LUCENTIS® (ranib
Report Publication Announcement
2025-05-23 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Q1 2025
2025-05-08 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Q1 2025
2025-05-08 English
Announcement from the annual general meeting in Xbrane Biopharma AB
AGM Information
2025-05-05 English
Kommuniké från årsstämma i Xbrane Biopharma AB
AGM Information
2025-05-05 Swedish
Announcement from extra general meeting in Xbrane Biopharma AB
Declaration of Voting Results & Voting Rights Announcements
2025-04-14 English
Kommuniké från extra bolagsstämma i Xbrane Biopharma AB
M&A Activity
2025-04-14 Swedish
NOTICE OF ANNUAL GENERAL MEETING IN XBRANE BIOPHARMA AB
Proxy Solicitation & Information Statement
2025-04-02 English
KALLELSE TILL ÅRSSTÄMMA I XBRANE BIOPHARMA AB
Proxy Solicitation & Information Statement
2025-04-02 Swedish
Annual Report 2024
Annual Report FY 2024
2025-03-31 Swedish
KALLELSE TILL EXTRA BOLAGSSTÄMMA I XBRANE BIOPHARMA AB
AGM Information
2025-03-20 Swedish
Notice of Extra General Meeting in Xbrane Biopharma AB
AGM Information
2025-03-20 English
Xbrane har ingått ett avtal om att avyttra XB003 (Cimzia biosimilar-kandidat) samt delar av sin organisation till Alvotech för en total köpeskilling om 275 miljoner SEK
M&A Activity
2025-03-20 Swedish
Xbrane has entered into an agreement to sell XB003 (Cimzia biosimilar candidate) and parts of its organization to Alvotech for a total consideration of SEK 275 million
M&A Activity
2025-03-20 English
Audit Report / Information 2024
Audit Report / Information FY 2024
2025-02-20 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Q4 2024
2025-02-20 English
The number of shares and votes in Xbrane has changed as a result of 2,706,898 shares being issued during January through the exercise of warrants in December 2024.
Declaration of Voting Results & Voting Rights Announcements
2025-01-31 English
Antalet aktier och röster i Xbrane har förändrats till följd av att 2 706 898 aktier har emitterats under januari månad genom utnyttjande av teckningsoptioner i december 2025.
Declaration of Voting Results & Voting Rights Announcements
2025-01-31 Swedish
Xbrane Biopharma AB (publ) (“Xbrane” eller “bolaget) utser Jane Benyamin till tillförordnad Chief Financial Officer.
Board/Management Information
2025-01-09 Swedish
Xbrane Biopharma AB (publ) (“Xbrane” or “the company) appoints Jane Benyamin as acting Chief Financial Officer.
Board/Management Information
2025-01-09 English
Xbrane Biopharma AB (publ) (“Xbrane” eller “bolaget) utser Jane Benyamin till tillförordnad Chief Financial Officer.
Board/Management Information
2025-01-09 Swedish
Xbrane Biopharma AB (publ) (“Xbrane” or “the company) appoints Jane Benyamin as acting Chief Financial Officer.
Board/Management Information
2025-01-09 English